CYP51A1 and metabolic dysfunction-associated steatotic liver disease: Cyp51 LKOs exhibited advanced NAFLD features, such as oval cell-driven inflammation and periportal fibrosis, which are characteristic for non-alcoholic steatohepatitis (NASH) that may progress to life-threatening cirrhosis and hepatocellular carcinoma25.